help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ye, J.-M.
Right arrow Articles by Kraegen, E. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ye, J.-M.
Right arrow Articles by Kraegen, E. W.
Endocrinology Vol. 143, No. 12 4527-4535
Copyright © 2002 by The Endocrine Society


ARTICLE

Prior Thiazolidinedione Treatment Preserves Insulin Sensitivity in Normal Rats during Acute Fatty Acid Elevation: Role of the Liver

Ji-Ming Ye, Georgia Frangioudakis, Miguel A. Iglesias, Stuart M. Furler, Bronwyn Ellis, Nicholas Dzamko, Gregory J. Cooney and Edward W. Kraegen

Garvan Institute of Medical Research, St. Vincent’s Hospital, Sydney, New South Wales 2010, Australia

Address all correspondence and requests for reprints to: Dr. Ji-Ming Ye, Diabetes and Obesity Research Program, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, Sydney, New South Wales 2010, Australia. E-mail: j.ye{at}garvan.org.au.

Thiazolidinediones lower lipids, but it is unclear whether this is essential for their insulin-sensitizing action. We investigated relationships between lipid-lowering and insulin-sensitizing actions of a thiazolidinedione. Normal rats were pretreated with or without Pioglitazone (Pio, 3 mg/kg·d) for 2 wk. Insulin sensitivity was assessed by hyperinsulinemic-euglycemic clamp with elevation of free fatty acids (FFA) by Intralipid/heparin infusion over 6 h. In untreated rats insulin sensitivity decreased by 46% over 3–6 h of elevated FFA, whereas it remained normal but with a 50% increase in FFA clearance in Pio-treated rats. After matching plasma FFA, insulin sensitivity was still partially (30%) protected in Pio-treated rats, substantially by maintaining insulin suppressibility of hepatic glucose output. This was associated with lower hepatic long-chain acyl-coenzyme A. Plasma adiponectin was increased 2-fold in Pio-treated rats and was negatively correlated with hepatic glucose output (r2 = 0.70, P < 0.001) and liver long-chain acyl-coenzyme A (r2 = 0.39, P < 0.005). Pio-induced muscle insulin sensitization was largely diminished after matching plasma FFA elevation, but insulin-stimulated protein kinase B phosphorylation was protected. We conclude that thiazolidinediones can protect against lipid-induced insulin resistance with a significant component (mainly liver) of the protective effect not requiring lipid lowering. This may be related to chronic elevation of adiponectin by thiazolidinediones.




This article has been cited by other articles:


Home page
J EndocrinolHome page
G. Frangioudakis and G. J Cooney
Acute elevation of circulating fatty acids impairs downstream insulin signalling in rat skeletal muscle in vivo independent of effects on stress signalling
J. Endocrinol., May 1, 2008; 197(2): 277 - 285.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
D. G. Haider, F. Mittermayer, G. Schaller, M. Artwohl, S. M. Baumgartner-Parzer, G. Prager, M. Roden, and M. Wolzt
Free fatty acids normalize a rosiglitazone-induced visfatin release
Am J Physiol Endocrinol Metab, November 1, 2006; 291(5): E885 - E890.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
S. Dhindsa, D. Tripathy, N. Sanalkumar, S. Ravishankar, H. Ghanim, A. Aljada, and P. Dandona
Free Fatty Acid-Induced Insulin Resistance in the Obese Is Not Prevented by Rosiglitazone Treatment
J. Clin. Endocrinol. Metab., September 1, 2005; 90(9): 5058 - 5063.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
M. E. Cleasby, N. Dzamko, B. D. Hegarty, G. J. Cooney, E. W. Kraegen, and J.-M. Ye
Metformin Prevents the Development of Acute Lipid-Induced Insulin Resistance in the Rat Through Altered Hepatic Signaling Mechanisms
Diabetes, December 1, 2004; 53(12): 3258 - 3266.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
J. Tonelli, W. Li, P. Kishore, U. B. Pajvani, E. Kwon, C. Weaver, P. E. Scherer, and M. Hawkins
Mechanisms of Early Insulin-Sensitizing Effects of Thiazolidinediones in Type 2 Diabetes
Diabetes, June 1, 2004; 53(6): 1621 - 1629.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
J. Sutinen, K. Kannisto, E. Korsheninnikova, R. M. Fisher, E. Ehrenborg, T. Nyman, A. Virkamaki, T. Funahashi, Y. Matsuzawa, H. Vidal, et al.
Effects of rosiglitazone on gene expression in subcutaneous adipose tissue in highly active antiretroviral therapy-associated lipodystrophy
Am J Physiol Endocrinol Metab, June 1, 2004; 286(6): E941 - E949.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
J. R. Colca, W. G. McDonald, D. J. Waldon, J. W. Leone, J. M. Lull, C. A. Bannow, E. T. Lund, and W. R. Mathews
Identification of a novel mitochondrial protein ("mitoNEET") cross-linked specifically by a thiazolidinedione photoprobe
Am J Physiol Endocrinol Metab, February 1, 2004; 286(2): E252 - E260.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2002 by The Endocrine Society